Trades on 2 secondary markets

858 Therapeutics

858 Therapeutics is a clinical-stage biotechnology company based in San Diego, California, developing first-in-class and best-in-class small-molecule therapies that target tumor dependencies in DNA damage response (DDR) pathways. Its lead program, ETX-19477, is an oral, potent, and selective PARG (p

minimal 8.1 / 100 0 APIs View provider profile →
CompanyBiotechTherapeuticsOncologyPrecision MedicineDrug Discovery

858 Therapeutics is an API provider whose private shares are listed on 2 secondary markets: EquityZen, Nasdaq Private Market.

Where It Trades

EZ EquityZen View listing → N Nasdaq Private Market View listing →

Listing data is compiled from the public marketplace pages of Forge Global, Hiive, EquityZen, Nasdaq Private Market, and Augment. A listing indicates that a venue has published a page for this company — it is not an offer, a quote, or investment advice, and APIs.io has no affiliation with any venue.